Saint Luke’s Michael & Marlys Haverty Cardio Metabolic Center of Excellence
A New Approach to Heart Disease and Diabetes
The Cardio Metabolic Center of Excellence is designed to treat cardiovascular complications in patients with type 2 diabetes, pre-diabetes, and other related comorbidities, including myocardial infarction, heart failure, stroke, and peripheral vascular disease.
The treatment of this group requires coordinated care by a multidisciplinary team, which can be difficult to deliver in typical clinical settings. At this one-of-a-kind clinic, patients are managed in close collaboration with their primary care teams and specialists such as endocrinologists and nephrologists.
Diabetes and Cardiovascular Disease: A Dangerous Combination
Those with diabetes have a two to four times greater risk for developing coronary artery disease and stroke. And one-third of patients older than 35 with diabetes have established cardiovascular disease. Despite advances in medical care, cardiovascular disease remains the leading cause of death in those with diabetes.
Having diabetes and heart disease together can result in life-threatening complications or additional cardiac events or strokes. Cardiovascular disease and metabolic disorders such as diabetes share critical risk factors that make complications more likely if not well controlled. These shared risk factors include: high cholesterol, high blood pressure, obesity, tobacco use and lack of physical activity. Cardiovascular injury can happen long before the official diagnosis of diabetes, making it vitally important to begin cardiovascular risk reduction behaviors as soon as possible.
New Treatments for Cardio Metabolic Disease
Those with diabetes can benefit from a comprehensive treatment approach that targets cardiovascular risk reduction. This can be achieved through numerous therapeutic options, such as blood pressure management strategies, lipid-lowering therapies, agents developed for glucose lowering with demonstrated cardiovascular benefits, and compounds that target inflammation.